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Abstract
Background: Molecular therapies that target genetic abnormalities in leukemic cells and their affected signaling
pathways have been emerging in pediatric acute lymphoblastic leukemia (ALL). Glycogen synthase kinase-3b (GSK-
3b) has recently been found to positively regulate the activity of nuclear factor-B (NF-B). Here, we investigated
the relationship between GSK-3b inhibition and NF-B in apoptosis of pediatric primary leukemia cells obtained
from 39 newly diagnosed ALL children in China.
Methods: Bone marrow mononuclear cells (BMMC) were isolated by density gradient centrifugation from the
heparinized aspirates of children with ALL. We used immunofluorescence staining to detect nuclear GSK-3b in
these cells. After treatment with chemically distinct GSK-3b inhibitors in vitro, NF-B transcriptional activity was
identified by means of western blotting and electrophoretic mobility shift assay (EMSA). NF-B-mediated apoptosis
was detected by Annexin V-PE/7-AAD double-staining flow cytometry. The expression level of the survivin gene
was detected by reverse-transcriptase polymerase chain reaction (RT-PCR).
Results: GSK-3b significantly accumulates in the nuclei of ALL cells than in the nuclei of control cells. Cell death
induced by GSK-3b inhibition in ALL cells was mediated by a downregulation of NF-B p65 transcriptional activity.
GSK-3b inhibition significantly decreased the expression of the NF-B target gene survivin.
Conclusions: These results indicate that inhibition of GSK-3b downregulates the NF-B activation pathway, leading
to suppression of the expression of an NF-B-regulated gene and promotion of apoptosis in ALL cells in vitro.
Furthermore, our findings suggest that GSK-3b or NF-B is a potential therapeutic target in the treatment of
pediatric ALL.
Introduction
Acute lymphocytic leukemia (ALL) is the most common
malignancy diagnosed in children, and it accounts for
approximately one-third of all pediatric cancers.
Although contemporary treatments cure more than 80%
of children with ALL, some patients require intensive
treatment and many patients still develop serious acute
and late complications because of the side effects of the
treatments [1]. Therefore, new treatment strategies are
needed to improve not only the cure rate but also the
quality of life of these children [2].
Glycogen synthase kinase-3 (GSK-3) is a serine/
threonine protein kinase, whose activity is inhibited by a
variety of extracellular stimuli including insulin, growth
factors, cell specification factors, and cell adhesion [3-5].
Two homologous mammalian GSK-3 isoforms are
encoded by different genes, GSK-3a and GSK-3b.
Recently, GSK-3 has been recognized as a key compo-
nent of a diverse range of cellular functions essential for
survival [6]. Fibroblasts from GSK-3b-deficient embryos
were sensitized to apoptosis and showed reduced
nuclear factor-B (NF-B) function [7]. Furthermore, it
has been shown that GSK-3b is a prosurvival factor in
pancreatic tumor cells, partly through its ability to regu-
late the NF-B pathway [8]. These findings suggest a
role for GSK-3b (but not GSK-3a) in the regulation of
NF-B activation. Recent experimental evidence has
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suggested that inhibition of GSK-3b abrogates NF-B
binding to its target gene promoters through an epige-
netic mechanism and enhances apoptosis in chronic
lymphocytic leukemia (CLL) B cells ex vivo [9]. Conse-
quently, inhibition of GSK-3b activity has been proposed
to play a role in the regulation of the NF-B signaling
pathway that elicits cellular survival responses.
However, little is currently known about the signifi-
cance of GSK-3b to pediatric ALL cell survival. ALL
initiates and progresses in the bone marrow (BM). In
the present study, we demonstrated that GSK-3b accu-
mulates in the nuclei of primitive pediatric ALL cells
from the BM. GSK-3b inhibition leads to suppression of
NF-B transcriptional activity and induces apoptosis




Fresh ALL samples were obtained from 39 children with
newly diagnosed acute lymphoblastic leukemia, with 11
normal BM samples as control, in Affiliated Children’s
Hospital, Chongqing Medical University. The diagnosis
of ALL was based on morphology, immunology, cytoge-
netic, and molecular classification. The informed con-
sent was obtained from parents, guardians, or patients
(as appropriate).
Isolation of leukemia cells and cell culture
Bone marrow mononuclear cells (BMMC) were isolated
from heparinized aspirates by Ficoll-Hypaque density
gradient centrifugation within 24 h after sampling. To
remove adherent cells, BMMC were suspended in RPMI
1640 medium supplemented with 20% fetal calf serum
(FCS) and incubated in plastic dishes at 37°C for 24 h
before collection of nonadherent cells. These ALL cells
were then either used immediately for the laboratory
studies described below or cryopreserved in RPMI 1640
medium with 20% FCS and 10% dimethyl sulfoxide
(DMSO) and stored in liquid nitrogen until use. If
necessary, leukemic samples were further enriched to
more than 90% leukemic blasts by removing nonmalig-
nant cells with immunomagnetic beads [10].
Reagents and antibodies
The GSK-3b inhibitors SB216763, and lithium chloride
(LiCl) were obtained from Sigma, USA. A 20 mg/ml
solution of SB216763 was prepared in dimethyl sulfoxide
(DMSO), stored in small aliquots at -20°C, and then
thawed and diluted in cell-culture medium as required.
LiCl was dissolved in RPMI 1640 and used at final con-
centrations of 5 and 10 mM. The high-quality fetal
bovine serum and RPMI 1640 medium were products of
Gibco Company, USA. RNAiso Plus, Reverse
Transcription PCR kits, and primers were products of
TaKaRa Biotechnology, Dalian, China. DyLight 549-
conjugated goat anti-rabbit IgG and Hoechst 33342
were obtained from CWBio, Beijing, China. Antibodies
for immunoblot analysis were obtained from the follow-
ing suppliers: GSK-3b and NF-B p65 from Cell Signal-
ing Technology, USA; survivin, b-actin, histone, and
goat anti-rabbit IgG-horseradish peroxidase (HRP) from
Santa Cruz Biotechnology, CA.
Analysis of GSK-3b expression in ALL cells by
immunofluorescence microscopy
BMMC that had been attached to glass slides by cyto-
centrifugation (StatSpin InC, USA) were fixed with 4%
paraformaldehyde in phosphate-buffered saline (PBS),
permeabilized with 0.3% Triton X-100 for 10 min at
room temperature, and blocked with 3% bovine serum
albumin (BSA) for 30 min. The cells were subsequently
subjected to immunofluorescence staining to detect
GSK-3b expression with the same primary antibody
(diluted 1:200) used for immunoblotting. After a rinse in
PBS, cells were incubated with secondary DyLight 549-
conjugated goat anti-rabbit IgG antibody. Nuclei were
counterstained with Hoechst 33342. SlowFade mounting
medium was used. Images were acquired using the Leica
Application Suite on a fluorescence microscope (Olym-
pus, Japan) equipped with a 40 ×/0.75 oil DIC objective.
Western blotting
Leukemic cells (1 × 107) undergoing different treatments
were rinsed with PBS and lysed in buffer. Nuclear/Cyto-
solic fractionation was performed using nuclear-cytosol
extraction kit (KENGEN Biotechnology, Nanjing, China)
according to the manufacturer’s instructions. Protein
sample concentration was quantified by the BCA
method and an equal amount (30 μg of cytosolic or
nuclear protein extract) of proteins was loaded in each
well of a 10% SDS polyacrylamide gel. Cell extracts were
separated by polyacrylamide gel electrophoresis (PAGE),
and transferred to polyvinylidene difluoride membrane
(PVDF). Primary antibodies against GSK-3b, NF-B p65,
survivin, b-actin, and histone were used. HRP-conju-
gated anti-IgG was used as the secondary antibody.
Western blot band intensities were quantified using
Quantity One software (Bio-Rad Laboratories, Inc.,
USA).
Electrophoretic mobility shift assays (EMSA) for NF-B
Nuclear lysates were prepared and protein concentra-
tions were measured by the BCA protein assay accord-
ing to the manufacturer’s manual. Equivalent amounts
of nuclear extract proteins (2 μg) were preincubated in
1 μl of binding buffer for 20 min at room temperature.
Then, a biotin-labeled oligonucleotide probe was added,
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and the reaction mixture was incubated for 20 min at
room temperature. For reactions involving competitor
oligonucleotides, the unlabeled competitor and the
labeled probes were premixed before addition to the
reaction mixture. The samples were analyzed on 6.5%
acrylamide gels and electrophoresis was carried out at
180 V for 70 min. Gel contents were transferred to
binding-membrane, dried, incubated with streptavidin-
HRP, and exposed with an intensifying screen.
Reverse-transcriptase polymerase chain reaction analysis
(RT-PCR)
Total RNAs were extracted according to the manufac-
turer’s instructions and were reverse-transcribed using the
PrimeScript RT reagent Kit (TaKaRa, Dalian, China). Of a
20 μl cDNA reaction, 5 μl was used as template for ampli-
fication with the following specific primers. For human
survivin forward: 5’-TCCACTGCCCCACTGAGAAC-3’
and reverse 5’-TGGCTCCCAGCCTTCCA-3’; for human
GAPDH forward: 5’-CAGCGACACCCACTCCTC-3’ and
reverse 5’-TGAGGTCCACCACCCTGT-3’. The PCR was
performed with the first denaturation step at 94°C for 5
min, and 35 cycles of denaturation at 94°C for 1 min,
annealing at 60°C for 30 s, and extension at 72°C for 1
min. The PCR reaction products were detected with gel
electrophoresis and ultraviolet transillumination.
Apoptosis assay
BMMC (1 × 106 cells) were exposed to GSK-3b inhibitors
or a matched concentration of diluents. After the treat-
ment, cells were rinsed twice in cold PBS, resuspended in
binding buffer, and then analyzed for apoptosis level by a
PE-labeled Annexin-V/7-AAD assay. These cells were
directly analyzed in a FACScan (BD FACS Calibur Co.,
USA) with a sample size of at least 10,000 cells gated on
the basis of forward and side scatter. Storing and proces-
sing of data were accomplished using FACScan software.
Statistical analysis
Results are expressed as mean ± standard deviation. Sta-
tistical analysis was conducted using SPSS 15.0 software.
Differences between groups were examined for statistical
significance using a one-way analysis of variance and
Student’s t-test; P values less than 0.05 were considered
statistically significant.
Results
GSK-3b accumulated in the nucleus of primary ALL cells
Using immunofluorescence staining, we identified the
localization of GSK-3b in ALL BMMC in 8 children
with ALL. As shown in Figure 1, we found nuclear
accumulation of GSK-3b in 6 primary pediatric ALL
BMMC samples, whereas it was not detected in the
nucleus of control BMMC.
Inhibition of GSK-3b suppressed the binding of NF-B to
the DNA in ALL cells
GSK-3b has been shown to play a critical role in NF-
B-mediated survival of cancer cells. The aberrant accu-
mulation of GSK-3b in nuclei of ALL cells prompted us
to examine the effect of GSK-3b inhibition on NF-B
activity. Using primary ALL cells, we tested ex vivo the
effect of 2 chemically distinct small-molecule inhibitors
of GSK-3b: SB216763 (ATP-competitive, arylindolema-
leimide) [11], and LiCl (non-ATP-competitive) [12].
Forty-eight hours after GSK-3b inhibitors treatment, we
estimated the level of GSK-3b inhibition by detection of
the cytosolic/nuclear level of GSK-3b by western blot.
We found that both the distinct GSK-3b inhibitors can
decrease the level of GSK-3b in nuclear extracts of ALL
cells (Figure 2). With the same treatments, nuclear levels
of NF-B p65 in ALL cells were not significantly chan-
ged (Figure 2). To further investigate the role of GSK-
3b in the regulation of NF-B activity, we detected NF-
B DNA binding activity by EMSA. The data show that
GSK-3b inhibition in ALL cells decreased the binding of
NF-B p65 to its target gene promoter (Figure 3).
Taken together, these results suggest that GSK-3b
affects NF-B activity at the transcriptional level in
pediatric ALL cells.
Pharmacologic inhibition of GSK-3b induced apoptosis in
ALL cells
Since NF-B is a potential target of GSK3b-dependent
cell survival pathway, we detected apoptotic cells as an
Annexin-V+/7-AAD+ population within DMSO or
SB216763-treated malignant cells cultured ex vivo from
each of the 11 patients with ALL by using Annexin-V
staining and flow cytometry. Although the mean num-
ber of apoptotic cells was 12% in DMSO-treated ALL
cells, the apoptotic cell fraction in the SB216763-treated
cells was significantly higher; the mean number of apop-
totic cells reached 36% (SB216763, 5 μM), 52%
(SB216763, 10 μM) and 70% (SB216763, 15 μM) after
48 h of exposure (Figure 4A, B; P < 0.001). It demon-
strated that the number of apoptotic cells dose-depen-
dently increased with SB216763 treatment. We also
evaluated the apoptotic effect of LiCl, another GSK-3b
inhibitor, on ALL cells. LiCl, at subtoxic concentrations,
induced NF-B-mediated apoptosis in a dose-dependent
manner (Figure 4C; P < 0.05). These results confirmed
that GSK-3b suppression leads to ALL apoptosis.
GSK-3b inhibitors had no significant effect on cell
apoptosis in normal BMMC
To further evaluate whether GSK-3b inhibition specifi-
cally induced apoptosis in ALL cells, we examined the
effect of GSK-3b inhibitors on normal BMMC. GSK-3b
inhibition was previously shown to preserve umbilical
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cord blood stem cell activity [13]. However, consistent
with the localization of GSK-3b in the nuclei of normal
BMMC, we found that the number of apoptotic cells in
normal BMMC was not significantly changed in the pre-
sence or absence of GSK-3b inhibitors after 48 h of
treatment (Figure 4; P > 0.05). The results obtained with
GSK-3b inhibition in normal progenitors versus ALL
cells provide evidence of a significant therapeutic
selectivity.
Pharmacologic inhibition of GSK-3b decreased NF-B-
mediated expression of an antiapoptotic molecule in ALL
cells
Pharmacologic inhibition of GSK-3b induced apoptosis
in ALL cells, so we further investigated whether inhibi-
tion of GSK-3b affects NF-B-mediated expression of
the antiapoptotic gene survivin in cells from 10 patients
with ALL. We found that inhibition of GSK-3b resulted
in decreased mRNA and protein expressions of NF-B
Figure 1 Immunofluorescence staining of GSK-3b in ALL cells. Bone marrow samples were obtained from children with ALL and from
control patients. GSK-3b was probed with Dylight 549-labeled anti-rabbit secondary antibody (red fluorescence) and nuclei were counterstained
with Hoechst 33342 (blue fluorescence). Nuclear accumulation of GSK-3b in ALL cells was detected, whereas only cytoplasmic expression of GSK-
3b was observed in control cells.
Figure 2 Detection of GSK-3b and NF-B protein expression,
after 48 h of treatment with GSK-3b inhibitors, by western blot
assay. ALL cells were cultured in the presence of LiCl (10 mM) or
SB216763 (10 μM) for 48 h. Cytosolic and nuclear fractions were
prepared from the indicated samples. b-Actin and histone were
used as markers for the purity of the cytosolic and nuclear fractions,
respectively. GSK-3b inhibition led to depletion of GSK-3b nuclear
pool in ALL cells, whereas nuclear levels of NF-B p65 remained
unchanged. The data shown are representative of 3 independent
experiments. 1: untreated ALL cells; 2: ALL cells treated with NaCl; 3:
ALL cells treated with LiCl (10 mM); 4: ALL cells treated with DMSO;
5: ALL cells treated with SB216763(10 μM).
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target gene survivin in ALL cells relative to control cells
(Figure 5). After completion of these experiments, we
summarized the data and represented it as a mean value
(Figure 5 legend). SB216763 (10 μM) and LiCl (10 mM)
treatment resulted in a 47.7% and 25% reduction in sur-
vivin mRNA levels, respectively. Moreover, the levels of
survivin mRNA decreased dose-dependently after treat-
ment with both LiCl and SB216763. These results indi-
cate that the inhibition of GSK-3b does not affect the
nuclear accumulation of NF-B p65 but might alter the
ability of NF-B to regulate target gene promoters in
ALL cells.
Discussion
GSK-3b has recently been shown to be a crucial enzy-
matic regulator of cancer cell survival in human tumori-
genesis [14,15]. GSK-3b protein is known to be
overexpressed in human prostate [16], pancreatic [17],
and colon [14] carcinomas. Normally, GSK-3b is
expressed in the cytoplasm of cells. Recent studies have
shown that GSK-3b could shuttle from the cytoplasm to
the nucleus in pancreatic cancer cell lines and in most
poorly differentiated human pancreatic adenocarcinomas
[17], and in human CLL B cells [9]. In this study, we
found aberrant nuclear accumulation of GSK-3b in cells
obtained from children with ALL, whereas GSK-3b was
not detected in the nucleus of control cells.
GSK-3b transposition was thought to participate in
the regulation of gene transcription through the phos-
phorylation of transcription factors [18]. NF-B, an
important transcription factor also involved in the reg-
ulation of cell proliferation, differentiation, and apop-
tosis, is deregulated in many human tumors [19,20].
Previous studies have suggested that NF-B transcrip-
tional activity is regulated by GSK-3b [7]. Genetic
depletion of GSK-3b by RNA interference suppresses
basal NF-B transcriptional activity, leading to
decreased pancreatic cancer cell proliferation and sur-
vival [8]. Recently, it has been demonstrated that GSK-
3b positively regulates NF-B-mediated drug resistance
in acute myeloid leukemia (AML) [21]. In this study,
we tested ex vivo the effect of 2 chemically distinct
small-molecule inhibitors of GSK-3b at subtoxic con-
centrations: LiCl, a well-known GSK-3b inhibitor, and
SB216763, a widely used maleimide-containing GSK-3b
inhibitor. Using the pharmacological inhibitors of
GSK-3b, we estimated the level of GSK-3b inhibition
by detecting the protein levels of GSK-3b in cytosolic
and nuclear extracts through western blot assay. In
ALL cells, we found that both inhibitors led to deple-
tion of the nuclear pool of GSK-3b, whereas no change
was found in the cytoplasm extract. Moreover, we
found that GSK-3b inhibition in ALL cells did not pre-
vent NF-B relocation from the cytoplasm to the
nucleus, but the inhibition affected the transcriptional
repression of NF-B, as shown by EMSA analysis.
Similar to previous studies [7], our studies on pediatric
ALL cells show that NF-B can be regulated by GSK-
3b at the level of the nuclear transcriptional complex.
The exact mechanism by which GSK-3b affects NF-B
transcriptional activity is still unknown. GSK-3b influ-
ences NF-B-mediated gene transcription in pancreatic
cancer cells at a point distal to the IB kinase complex
[7]. Recent data have demonstrated that GSK-3b may
contribute to p65/p50 binding to the promoters and
transcriptional activation of NF-B in CLL cells by regu-
lating histone modification [6]. However, the underlying
mechanism by which GSK-3b regulates p65 NF-B
binding to target gene promoters has not been defined.
NF-B is known as an important factor of cancer cell
survival in human tumorigenesis [22]. In this report, we
found that GSK-3b suppression sensitized ALL cells to
NF-B-mediated apoptosis. Both SB216763 and LiCl
have been shown to induce ALL cells apoptosis. In addi-
tion, we observed that there is no significant effect on
apoptosis induced by GSK-3b inhibitors in control
BMMC. A relevant finding was that GSK-3b was not
detected in the nucleus of control BMMC but was
detected in the nuclei of ALL cells. Taken together, our
Figure 3 Effects of GSK-3b inhibitors on DNA binding activity
of NF-B in nuclear extracts of ALL cells. After 48 h of treatment
with GSK-3b inhibitors, ALL cells nuclear extracts were prepared and
assayed for NF-B activation by EMSA as described under
“Methods.” GSK-3b inhibitors resulted in a reduction in NF-B DNA
binding activity when compared to control condition (untreated
ALL cells). The data shown are representative of 3 independent
experiments. 1: negative control; 2: positive control; 3: untreated ALL
cells; 4: ALL cells treated with LiCl (10 mM); 5: ALL cells treated with
SB216763 (10 μM).
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Figure 4 Inhibition of GSK-3b induces apoptosis in ALL but not control cells. (A) ALL cells were treated for 48 h with DMSO or SB216763
at indicated concentrations. Cells were assayed for apoptosis using Annexin V-PE/7-AAD staining by flow cytometry. (B) We found that inhibition
of GSK-3b in ALL cells consistently resulted in a dose-dependent increase in the number of apoptotic cells. (C) ALL cells were treated for 48 h
with NaCl or LiCl at indicated concentrations, then assayed for apoptosis using Annexin-V-PE/7-AAD staining as determined by flow cytometry.
(D) Each GSK-3b inhibitor was added to control BMMC at the initiation of the culture at a variety of concentrations as indicated on the graph.
LiCl and SB216763 had no significant effect on cell apoptosis in normal BMMC. Columns, mean; bars, SD. *P < 0.05, **P < 0.01 vs. control. All
assays were performed in triplicate.
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results provide evidence of GSK-3b as a novel potential
therapeutic target in the treatment of ALL.
Survivin, which is known to be regulated by NF-B
[23], plays a major role in the suppression of apoptosis
[24]. Our previous experiments have shown that the
expression of the antiapoptotic gene survivin signifi-
cantly increased in children with newly diagnosed acute
leukemia (data not shown). Using malignant cells
obtained from children with ALL, we have analyzed the
effect of GSK-3b inhibition on NF-B-dependent gene
expression involved in the survival of ALL cells. We
found that both SB216763 and LiCl could inhibit the
expression of survivin, thereby promoting cell apoptosis.
Conclusions
Our data demonstrated for the first time the involvement
of GSK-3b in pediatric ALL cells, and not in adult leuke-
mia cells, although GSK-3b inhibition played a similar
role in inducing apoptosis in leukemia cells via in vitro
activation of NF-B. Thus, inhibition of GSK-3b and of
its target NF-B signaling pathway could represent a new
promising approach for pediatric ALL therapy.
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